J. Moretta

发表

[Having a child and PND/PGD access in women with a BRCA1/2 mutation? Different approach whether ill or healthy].

L. Huiart, C. Julian‐Reynier, C. Noguès, 2014, Bulletin du cancer.

Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis

P. Viens, H. Sobol, C. Popovici, 2016, Familial Cancer.

Highly favorable outcome in BRCA-mutated metastatic breast cancer patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation

F. Bertucci, P. Viens, C. Tarpin, 2016, Bone Marrow Transplantation.

A new hybrid record linkage process to make epidemiological databases interoperable: application to the GEMO and GENEPSO studies involving BRCA1 and BRCA2 mutation carriers

F. Révillion, Chloé-Agathe Azencott, N. Sevenet, 2020, BMC Medical Research Methodology.

Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis

P. Viens, H. Sobol, C. Popovici, 2016, Familial Cancer.

[Personalized medicine and breast cancer: anticipatory medicine, prognostic evaluation and therapeutic targeting].

F. Bertucci, A. Gonçalves, F. Eisinger, 2013, Bulletin du cancer.

Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study

R. Eeles, J. Hopper, D. Easton, 2021, American journal of obstetrics and gynecology.

Highly favorable outcome in BRCA-mutated metastatic breast cancer patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation

F. Bertucci, P. Viens, C. Tarpin, 2017, Bone Marrow Transplantation.

Hereditary diffuse gastric cancer syndrome: improved performances of the 2015 testing criteria for the identification of probands with a CDH1 germline mutation

D. Stoppa-Lyonnet, C. Tlemsani, B. Buecher, 2015, Journal of Medical Genetics.

Is the controversy on breast cancer as part of the Lynch-related tumor spectrum still open?

S. Olschwang, J. Tinat, P. Grandval, 2012, Familial Cancer.

[The French Genetic and Cancer Consortium guidelines for multigene panel analysis in hereditary breast and ovarian cancer predisposition].

P. Pujol, C. Lasset, P. Berthet, 2018, Bulletin du cancer.

Hereditary diffuse gastric cancer syndrome: improved performances of the 2015 testing criteria for the identification of probands with a CDH1 germline mutation

D. Stoppa-Lyonnet, C. Tlemsani, B. Buecher, 2015, Journal of Medical Genetics.